• Sample Page

Targeting the ubiquitin–proteasome system for cancer therapy

Foxd1

In a recently available problem of the by demonstrating that like

September 30, 2018 by Katherine Lewis Leave a Comment

In a recently available problem of the by demonstrating that like imatinib [2], nilotinib can inhibit LCK, a Src-family kinase that takes on a critical part in TCR activation [3]. Inhibition of LCK by nilotinib and imatinib was analysed by analyzing the effects of every medication on LCK phosphorylation of the substrate peptide. Dynamic LCK … [Read more…]

Posted in: Blogging Tagged: 155213-67-5 IC50, Foxd1

Although the usage of recombinant hepatitis B virus surface (HBsAg) protein

July 22, 2017 by Katherine Lewis Leave a Comment

Although the usage of recombinant hepatitis B virus surface (HBsAg) protein vaccine has successfully reduced global hepatitis B infection there are still a number of vaccine recipients who do not develop detectable antibody responses. original HBs-L DNA vaccine the HBs-L(T) DNA vaccine improved secretion in cultured mammalian cells and generated significantly enhanced HBsAg-specific antibody and … [Read more…]

Posted in: Blogging Tagged: Foxd1, Mubritinib

Copyright © 2019 Targeting the ubiquitin–proteasome system for cancer therapy.

Omega Child WordPress Theme by